Forty-six cases of nasopharyngeal carcinoma treated with 50 Gy radiotherapy plus hematoporphyrin derivative: 20 years of follow-up and outcomes from the Sun Yat-sen University Cancer Center

Table 3 The 5-, 10-, and 20-year survival rates for the 46 NPC patients at different stages

Item	OS rate (%)			P value	LRFS rate (%)			P value	DMFS rate (%)			P value	DFS rate (%)			P value
Item	5-year	10-year	20-year	P value	5-year	10-year	20-year	P value	5-year	10-year	20-year	P value	5-year	10-year	20-year	P value
Clinical stage^a
I	66.7	66.7	66.7	0.979	66.7	66.7	66.7	0.019	100	100	100	0.072	66.7	66.7	66.7	<0.001
II	70.0	30.0	30.0		92.3	82.1	82.1		82.1	82.1	82.1		75.2	64.5	64.5
III	73.8	39.1	29.0		73.6	60.2	42.2		90.4	84.0	84.0		70.4	53.2	37.2
IV	85.7	42.9	14.3		25.7	25.7	25.7		31.2	31.2	31.2		0	0	0
T stage^a
T1	80.0	26.7	26.7	0.996	87.5	58.3	58.3	0.020	85.7	68.6	68.6	0.066	58.3	43.8	43.8	<0.001
T2	66.7	44.4	33.3		88.9	88.9	88.9		88.9	88.9	88.9		77.8	77.8	77.8
T3	72.7	36.4	30.3		72.1	64.9	45.4		89.9	89.9	89.9		68.6	49.7	39.7
T4	85.7	42.9	14.3		25.7	25.7	25.7		31.2	31.2	31.2		0	0	0
N stage^a
N0	58.3	29.2	29.2	0.992	80.8	80.8	80.8	<0.001	90.9	90.9	90.9	0.068	71.6	71.6	71.6	0.005
N1	67.9	39.3	31.2		75.6	69.8	55.9		78.3	78.3	78.3		55.4	50.3	40.3
N2	83.3	50.0	16.7		60.0	20.0	0		80.0	60.0	60.0		60.0	20.0	0
N3	0	0	0		0	0	0		0	0	0		0	0	0

NPC nasopharyngeal carcinoma; OS overall survival; LRFS local recurrence-free survival; DMFS distant metastasis-free survival; DFS disease-free survival
^a As defined by the criteria of the seventh edition of the AJCC staging system for NPC

ISSN: 2523-3548